Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. The company’s lead product candidate is TA-ERT (tralesinidase alfa enzyme replacement therapy), a fusion protein designed to treat Mucopolysaccharidosis Type IIIB (MPS IIIB), also known as Sanfilippo Syndrome Type B. TA-ERT is administered via intracerebroventricular infusion to restore enzyme activity in the central nervous system. The company seeks regulatory approval in the United States and Europe and intends to commercialize its products globally through its own organization in North America, the EU, and the UK, while utilizing regional strategic collaborations and third-party distributors in other international markets. Founded in April 2016, the company targets serious diseases with clear biology and suboptimal treatment options.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage sprucebio.com
Sector Healthcare IR page investors.sprucebio.com
Tags
neurological disorders, enzyme replacement therapy, rare diseases, mps iiib, sanfilippo syndrome, biologics, small molecules, central nervous system, genetic diseases, pediatric care, TA-ERT, tralesinidase alfa, rhNAGLU, Sanfilippo Syndrome Type B
Press page —

Metrics

Valuation  
Market cap $ 139.62M
Market cap (USD) $ 139.62M
P/E -1.44
PEG —
P/BV 2.11
P/S 28.43
P/OCF -2.73
P/FCF -4.19
Dividend yield —
Turnover / mcap —
Returns  
ROE -109.2%
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) —
Debt/Equity 11.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 42
Quality score -45.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 0 4.911M 10.089M — — — —
Net profit -38.966M -53.036M -47.919M -46.18M -42.292M -29.539M -13.088M
Free cash flow -33.327M -55.964M -33.282M -41.691M -35.97M -27.593M -12.621M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 87.11 0.42 2.93 1.1 4.46 24.31 —
Price performance 12m 206.4 -0.86 1.67 -0.75 -0.82 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — 0.00 — — —
Borrowings, current (USD) 1.25M 2.55M 0.00 1.62M 1.62M 1.62M 0.00
Borrowings, non-current (USD) 3.19M 1.92M 4.88M 3.29M 1.72M 124,000 0.00
Lease liabilities (USD) — 1.9M 1.65M 1.4M 1.27M 1.02M 736,000
Cash and deposits (USD) 3.92M 157M 42.7M 24.5M 96.3M 38.8M 48.9M
Right-of-use assets (USD) — 1.79M 1.48M 1.4M — — —
Net debt (borrowings + leases - cash) (USD) 521,000 -151M -36.2M -18.2M -91.7M -36M -48.2M
Cash flow detail
Operating cash flow (USD) -12.6M -27.5M -35.9M -41.7M -33.3M -56M -33.3M
Purchases of property, plant and equipment (USD) -4,000 -74,000 -93,000 -8,000 -7,000 0.00 —
Change in payables (cash effect) (USD) -226,000 3.73M 1.15M -1.4M 1.91M -2.04M -352,000
Interest paid (cash effect) (USD) -20,000 -192,000 -207,000 -266,000 -369,000 -225,000 -68,000
Share-based compensation (USD) 196,000 755,000 3.96M 3.63M 4.62M 5.35M 2.57M
Free cash flow (OCF - PPE - intangibles) (USD) -12.6M -27.6M -36M -41.7M -33.3M -56M —
Income detail
Research and development expense (USD) 10.8M 23.9M 30.7M 35.2M 49.4M 46.4M 19.5M
↳ 5y CAGR +33.8% -3.9%
Total comprehensive income (USD) — -29.5M -42.5M -46.6M -47.4M -53M —
Comprehensive income to owners (USD) — -29.5M -42.5M -46.6M -47.4M -53M —
Reported Mar 22, 2021 Mar 14, 2022 May 11, 2022 May 15, 2023 Mar 18, 2024 Apr 15, 2025 Mar 9, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Biologics License Application (“BLA”) Submission for Tralesinidase Alfa Enzyme Replacement Therapy (“TA-ERT”) for the Treatment of MPS IIIB Remains on Track for December 2026

Amended Avenue Loan Agreement to Increase Tranche 2 Availability to $15 Million and Extend Interest-Only Period

Announced Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences

South San Francisco, Calif. — November 9, 2026 — Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2026, and provided corporate updates.

“We are executing with discipline as we complete the final steps toward our planned BLA submission for TA-ERT in December, which we believe will be a defining milestone for Spruce and for the children and families living with MPS IIIB,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences.

October 15, 2026

Download PDF

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 15, 2026-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in a fireside chat at the Craig-Hallum Biotech Catalyst Conference on October 22, 2026.

An archived copy of the webcast will be available on the events section of the Company’s website for approximately 90 days following the live presentation.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. Spruce’s lead product candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is in late-stage development for the treatment of MPS IIIB, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261015117605/en/

Media Heidi Chokeir Inizio Evoke Comms [email protected] [email protected]

Investors Monique Kosse Gilmartin Group [email protected] [email protected]

Source: Spruce Biosciences, Inc.

Investors/Media

Contact

Investor Contact [email protected]

Sidebar Contact

Media Contact [email protected]

October 8, 2026

Download PDF

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 8, 2026-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data from Study 250-902 (NCT03227042), a prospective, multicenter, multinational, noninterventional, longitudinal natural history study designed to characterize disease progression in pediatric participants with severe, non-attenuated Sanfilippo Syndrome Type B (MPS IIIB) will be presented at the 55th Child Neurology Society (CNS) Annual Meeting, taking place October 14–17, 2026, in Montréal, Québec, Canada. The poster will be available on the Spruce Biosciences website following the presentation.

CNS Annual Meeting Poster Presentation Details

Title: In-depth analyses of cognition, motor, communication, and adaptive natural history disease course in participants with MPS IIIB **Session Type:**Poster Presentation – Neurodevelopmental Disorders Poster Number: 235 Presentation Date & Time: October 15, 2026, 12:30 p.m. – 1:45 p.m. EDT and 5:30 p.m. – 7:30 p.m. EDT **Presenter:**Ilyas Okur, M.D., Professor of Pediatrics and Pediatric Metabolism Specialist, Gazi University Faculty of Medicine, Ankara, Türkiye Authors: Ilyas Okur, M.D.; Fatih Ezgu, M.D.; Yin-Hsiu Chien, M.D., Ph.D.; Cara O’Neill, M.D., FAAP; Roberto Giugliani, M.D., Ph.D.; Can Ficicioglu, M.D., Ph.D.; Igor Nestrasil, M.D., Ph.D.; Irene J. Chang, M.D.; Elizabeth R. Jalazo, M.D.; Martha Solano, M.D.; Saba Sile, M.D.; Richard Kim, M.D.; Kirk Ways, M.D., Ph.D.; and Nicole Muschol, M.D.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. Spruce’s lead product candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is in late-stage development for the treatment of MPS IIIB, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, statements regarding the planned presentation of natural history data at the 55th Child Neurology Society Annual Meeting and the development of TA-ERT. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plan,” “will,” “believe,” “could,” “expect,” “on track,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Spruce’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Spruce’s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Spruce’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Spruce undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261008501925/en/

Media

Heidi Chokeir Inizio Evoke Comms [email protected] [email protected]

Investors

Monique Kosse Gilmartin Group [email protected] [email protected]

Source: Spruce Biosciences, Inc.

Investors/Media

Contact

Investor Contact [email protected]

Sidebar Contact

Media Contact [email protected]

Prompts

Spruce Biosciences, Inc. (ticker SPRB), listed in United States.

ETFs Holding Spruce Biosciences, Inc.

ETF Weight in ETF Shares Market value As of
FSEG 0.05% 53 $ 2,862.00 Jun 30, 2026
DCOR 0.00% 371 $ 15.912K Nov 12, 2026
AVSC 0.00% 1,274 $ 53.827K Nov 16, 2026